NASDAQ Framework: Amicus Therapeutics Inc.

Biotechnology company focused on rare diseases 1.

Amicus Therapeutics, Inc., incorporated in 2002 and headquartered in Princeton, New Jersey, is a biotechnology company dedicated to discovering, developing, and delivering medicines for rare diseases. The company's commercial product and product candidates include Galafold, an oral precision medicine for adults with Fabry disease, and Pombiliti + Opfolda for late-onset conditions. Amicus has established collaboration and license agreements with the University of Pennsylvania and GlaxoSmithKline to advance its research and development efforts in parvovirus gene therapy products 2.

2: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source

UNKNOWN

The provided facts do not specify whether Amicus Therapeutics Inc. is still led by its founders or if the founders are heavily involved 3 4 5 6.

3: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.74 percent of Amicus Therapeutics Inc shares are owned by insiders, and 106.72 percent are held by financial institutions. Campbell Bradley L, the President and CEO at Amicus Therapeutics Inc (FOLD) has sold 6,100 shares of firm on Jul 05 ’24 at a price of $10.00 against the total amount of $61029.0. In another inside trade, Campbell Bradley L, President and CEO of Amicus Therapeutics Inc (NASDAQ:FOLD) sold 1,400 shares of the firm on Jul 01 ’24 for a total worth of $14003.0 at a price of $10.00. An inside trade which took place on Jun 03 ’24, President and CEO of Amicus Therapeutics Inc Campbell Bradley L sold 7,500 shares of firm against total price of $75000.0 at the cost of $10.00 per share. View Source4: ×About Amicus About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Patient Advocacy Expanded Access Patient Advisory Boards Rare Stories Resources Programs & Pipeline Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Global Research Center Products Products & Services Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) AMICUS ASSIST® Responsibility Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Investors & Media Investor Relations Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Careers Careers Overview Who We Are Search View Source5: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source6: About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO View Source

MEDIUM RISK

Amicus Therapeutics Inc. shows signs of both potential and concern. On the positive side, the company has received upgraded stock ratings from financial institutions like Wells Fargo and Morgan Stanley, indicating confidence in its future performance 7. Additionally, it has a diverse pipeline of products and collaborations with reputable institutions 8. However, insider trading activities by the President and CEO suggest potential concerns about the stock's future performance 9. Furthermore, despite recent gains, investors from a year ago are still down 19%, indicating volatility and potential financial instability 10. Therefore, the financial situation of Amicus Therapeutics Inc. can be considered medium risk.

7: Wells Fargo raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The research report from Morgan Stanley has upgraded the stock from Equal-Weight to Overweight, with a price target set at $20. The stock was initiated by Morgan Stanley, who disclosed in a research note on September 09, 2022, to Equal-Weight and set the price objective to $14. In their research brief published April 13, 2022, Goldman analysts resumed the Amicus Therapeutics Inc stock to Neutral with a price target of $11. View Source8: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source9: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.74 percent of Amicus Therapeutics Inc shares are owned by insiders, and 106.72 percent are held by financial institutions. Campbell Bradley L, the President and CEO at Amicus Therapeutics Inc (FOLD) has sold 6,100 shares of firm on Jul 05 ’24 at a price of $10.00 against the total amount of $61029.0. In another inside trade, Campbell Bradley L, President and CEO of Amicus Therapeutics Inc (NASDAQ:FOLD) sold 1,400 shares of the firm on Jul 01 ’24 for a total worth of $14003.0 at a price of $10.00. An inside trade which took place on Jun 03 ’24, President and CEO of Amicus Therapeutics Inc Campbell Bradley L sold 7,500 shares of firm against total price of $75000.0 at the cost of $10.00 per share. View Source10: Investors in Amicus Therapeutics (NASDAQ:FOLD) from a year ago are still down 19%, even after 3.9% gain this past week View Source

NO

The provided facts do not indicate that Amicus Therapeutics Inc. is launching any new product offerings 11 12 13.

11: ×About Amicus About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Patient Advocacy Expanded Access Patient Advisory Boards Rare Stories Resources Programs & Pipeline Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Global Research Center Products Products & Services Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) AMICUS ASSIST® Responsibility Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Investors & Media Investor Relations Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Careers Careers Overview Who We Are Search View Source12: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source13: Our Products Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) Amicus Assist™ View Source

Amicus Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on the continued development and commercialization of its key products, Galafold and Pombiliti + Opfolda, which target rare diseases such as Fabry disease and late-onset conditions, respectively. The company has established significant collaboration and license agreements with the University of Pennsylvania and GlaxoSmithKline to further its research and development in parvovirus gene therapy products 14. Additionally, Amicus Therapeutics is actively involved in presenting its advancements and achievements at major healthcare conferences, such as the Goldman Sachs 45th Annual Global Healthcare Conference and the Bank of America 2024 Health Care Conference 15 16. The company has also received recognition for its pharmaceutical innovations, exemplified by the Prix Galien U.K. Award for Pombiliti + Opfolda 17.

14: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source15: Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference View Source16: Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference View Source17: Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product View Source

Sources

1: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source2: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source3: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.74 percent of Amicus Therapeutics Inc shares are owned by insiders, and 106.72 percent are held by financial institutions. Campbell Bradley L, the President and CEO at Amicus Therapeutics Inc (FOLD) has sold 6,100 shares of firm on Jul 05 ’24 at a price of $10.00 against the total amount of $61029.0. In another inside trade, Campbell Bradley L, President and CEO of Amicus Therapeutics Inc (NASDAQ:FOLD) sold 1,400 shares of the firm on Jul 01 ’24 for a total worth of $14003.0 at a price of $10.00. An inside trade which took place on Jun 03 ’24, President and CEO of Amicus Therapeutics Inc Campbell Bradley L sold 7,500 shares of firm against total price of $75000.0 at the cost of $10.00 per share. View Source4: ×About Amicus About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Patient Advocacy Expanded Access Patient Advisory Boards Rare Stories Resources Programs & Pipeline Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Global Research Center Products Products & Services Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) AMICUS ASSIST® Responsibility Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Investors & Media Investor Relations Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Careers Careers Overview Who We Are Search View Source5: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source6: About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO View Source7: Wells Fargo raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The research report from Morgan Stanley has upgraded the stock from Equal-Weight to Overweight, with a price target set at $20. The stock was initiated by Morgan Stanley, who disclosed in a research note on September 09, 2022, to Equal-Weight and set the price objective to $14. In their research brief published April 13, 2022, Goldman analysts resumed the Amicus Therapeutics Inc stock to Neutral with a price target of $11. View Source8: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source9: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.74 percent of Amicus Therapeutics Inc shares are owned by insiders, and 106.72 percent are held by financial institutions. Campbell Bradley L, the President and CEO at Amicus Therapeutics Inc (FOLD) has sold 6,100 shares of firm on Jul 05 ’24 at a price of $10.00 against the total amount of $61029.0. In another inside trade, Campbell Bradley L, President and CEO of Amicus Therapeutics Inc (NASDAQ:FOLD) sold 1,400 shares of the firm on Jul 01 ’24 for a total worth of $14003.0 at a price of $10.00. An inside trade which took place on Jun 03 ’24, President and CEO of Amicus Therapeutics Inc Campbell Bradley L sold 7,500 shares of firm against total price of $75000.0 at the cost of $10.00 per share. View Source10: Investors in Amicus Therapeutics (NASDAQ:FOLD) from a year ago are still down 19%, even after 3.9% gain this past week View Source11: ×About Amicus About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Patient Advocacy Expanded Access Patient Advisory Boards Rare Stories Resources Programs & Pipeline Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Global Research Center Products Products & Services Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) AMICUS ASSIST® Responsibility Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Investors & Media Investor Relations Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Careers Careers Overview Who We Are Search View Source12: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source13: Our Products Galafold®(migalastat) Pombiliti™ + Opfolda™(cipaglucosidase alfa-atga) (miglustat) Amicus Assist™ View Source14: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. View Source15: Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference View Source16: Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference View Source17: Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product View Source